Skip to main content

Markets News Screener Research Editorials Pricing About

⌘K

Sign in Start free

Not investment advice. Moatkeep provides data and educational content, not recommendations.

Financial glossary·Pricing·About·Disclaimer·Terms·Privacy·Cookies·Methodology·Support·Company directory·Companies by industry·Feed

© moatkeep 2026

Avalyn Pharma Inc. (AVLN) stock — financials, valuation and filings | Moatkeep

Companies/Nasdaq/AVLN

Avalyn Pharma Inc.

AVLN · Nasdaq

$30.59−3.26%

Close, 2026-11-12Close, 2026-11-12 · source: Databento · USD · figures not investment advice

Data under review

Priceex-date (0) · fiscal quarter (0)

Dividends: company filings (SEC EDGAR) and the historical exchange record.

State of incorporation: DE
Fiscal year end: Dec 31

Valuation snapshot

$1.36B

N/M

N/M

—

-18.66%

—

Close, 2026-11-12

Financials · latest year

Revenue•••••••••••••••

Gross profit•••••••••••••••

Operating income•••••••••••••••

Net income•••••••••••••••

Free cash flow•••••••••••••••

Read the full financial statements

Free accounts read five years of annual financials.

Source: SEC EDGAR (XBRL) · figures in USD millions

Related companies

NOMD — Nomad Foods Ltd ALG — ALAMO GROUP INC ENOV — Enovis CORP MESO — MESOBLAST LTD WWW — WOLVERINE WORLD WIDE INC PRLB — Proto Labs Inc ANAB — ANAPTYSBIO, INC AMPX — Amprius Technologies, Inc.